At Penn State University, researchers have created CaroFlex—a soft, stretchy implant no bigger than a fingertip—that could transform how doctors treat the roughly 10% of high blood pressure patients who don't respond to medication. The device uses gentle electrical pulses to calm an overactive reflex in the carotid artery, a major blood vessel in the neck, offering hope to millions trapped in a cycle of failed drug combinations.
High blood pressure affects nearly half of all American adults and remains a leading cause of heart disease. For most people, pills and lifestyle changes work reasonably well. But for about one in ten hypertension patients, drug-resistant hypertension becomes a stubborn, often lifelong condition—even combinations of three to five different medicines fail to bring relief. These patients have few good options beyond escalating medication doses with mounting side effects.
The innovation lies in targeting the baroreceptor reflex, a biological safety system in our arteries that automatically adjusts blood vessel tension when it senses pressure changes. The carotid sinus, a small section of the carotid artery in the neck, is packed with specialized nerve endings called baroreceptors that monitor these shifts. Stimulating these receptors with the right electrical signal can reset the system and lower blood pressure—a concept that a few commercial devices already explore. But those existing bioelectronics rely on rigid metals and plastics held in place with stitches, creating a fundamental problem: as arteries naturally stretch and shrink with each heartbeat, the hard materials cause cumulative tissue damage around the implant site.
Tao Zhou, a Wormley Family Early Career Assistant Professor of Engineering Science and Mechanics at Penn State, led the team in designing CaroFlex to solve this friction between body and technology. Instead of metal and plastic, they 3D-printed the device from hydrogel—a soft, jelly-like material that mimics the mechanical properties of biological tissue itself. Conductive hydrogels form the electrodes that deliver electrical stimulation, while adhesive hydrogels allow the device to stick directly to arterial tissue without stitches. Zhou explains the significance: "For many patients, even taking a combination of three to five medicines doesn't alleviate their high blood pressure. In these cases, bioelectronic devices that use electrical signals to modulate the body's natural response systems offer a promising form of alternative treatment."
Laboratory testing revealed remarkable durability. CaroFlex can stretch to more than twice its original size before failing—crucial for an implant that must flex with living tissue. The adhesive layer remained strong and stable even after six months of storage, suggesting it could maintain long-term effectiveness inside the body. When tested on tissue samples, the device performed as intended, engaging the baroreceptor reflex with gentle electrical frequencies that posed no toxicity risk.
The team's rodent studies showed the device relieved high blood pressure while causing significantly less damage to surrounding tissue than existing rigid alternatives. Their findings, published in Device, represent a meaningful step toward a new class of bioelectronics that work with the body rather than against it. For the millions of Americans whose blood pressure remains dangerously high despite medication, this soft-touch technology could mean finally having an option when pills alone aren't enough.